GlassScriptPhysician profile
Stephen Charles Smith
NPI 1417993486
$9,706.99
in general payments reported to CMS, 2019-2025
51 companies · $1,228 in 2025
The $1,228 reported for 2025 was more than what 88% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,334 · 2020: $1,369 · 2021: $1,573 · 2022: $775 · 2023: $608 · 2024: $1,819 · 2025: $1,228.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,655.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,655.18 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $1,168.15 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $821.43 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Glaxosmithkline, LLC. | $815.15 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Abbvie INC. | $762.48 | 2021-2025 | Vraylar, Ubrelvy |
| Novo Nordisk INC | $649.04 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| E.R. Squibb & Sons, L.L.C. | $588.29 | 2019-2025 | Camzyos, Eliquis |
| Amgen INC. | $529.94 | 2019-2025 | Evenity, Prolia, Tezspire |
| Lilly USA, LLC | $452.20 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Janssen Pharmaceuticals, INC | $390.40 | 2019-2024 | Xarelto |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $359.55 | 2019-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $346.41 | 2019-2025 | Jardiance |
| Amarin Pharma, INC. | $290.04 | 2019-2021 | |
| Esperion Therapeutics, INC. | $273.26 | 2020-2022 | |
| Pfizer INC. | $232.26 | 2019-2025 | |
| Biohaven Pharmaceuticals, INC. | $205.20 | 2020-2021 |
Show all 51 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Stephen Smith listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.